AIMS AND BACKGROUND: A dose-dense therapy with weekly paclitaxel given as a 1-hr infusion yielded a 53% overall response rate in breast cancer patients resistant to anthracyclines, with a remarkable lack of neutropenia (Seidman, 1998). We performed a monoinstitutional phase II trial in order to confirm these interesting results. PATIENTS AND METHODS: Eligibility criteria included advanced breast cancer and no taxane pretreatment. Paclitaxel was administered weekly at the dose of 90 mg/m2 (60 mg/m2 in patients at high risk of toxicity) by 1-hr i.v. infusion. Fifty-eight patients entered the trial. Median age was 54 years (range, 38-72). Performance status was good (median 1; range, 0-2). Fifty-two patients were pretreated with anthracyclines. RESULTS: A total of 1,004 weekly paclitaxel infusions were administered (median, 19 per patient; range, 4-43). The median delivered dose intensity was 67.4 mg/m2/week (range, 43-86). Twenty-eight of the 58 assessable patients obtained an objective response (48%), 15 had stable disease (26%) and 15 progressed (26%). The overall response rate was 48% (95% confidence interval, 35-61%) with 5 complete responses (8%). In anthracycline-pretreated patients, 23/52 (44%) responses were observed. Median duration of response was 5 months (range, 3-27). Toxicity was acceptable apart from a case of pulmonary embolism in a 70-year-old patient, 1 case of congestive heart failure in an anthracycline-pretreated patient aged 64, and 9 cases of G3 neutropenia. Peripheral neuropathy was observed in 38 patients (64%), usually of a mild grade; alopecia in 45 patients (78%) and onychopathy in 16 (28%), usually of a mild grade apart from 2 cases requiring treatment interruption. Tachycardia and atrial fibrillation occurred in a 55-year-old woman. CONCLUSIONS: Our data seem to confirm the activity and safety of this approach even in a heavily pretreated population of patients. Its combination with other active drugs needs to be further investigated in clinical trials.
AIMS AND BACKGROUND: A dose-dense therapy with weekly paclitaxel given as a 1-hr infusion yielded a 53% overall response rate in breast cancer patients resistant to anthracyclines, with a remarkable lack of neutropenia (Seidman, 1998). We performed a monoinstitutional phase II trial in order to confirm these interesting results. PATIENTS AND METHODS: Eligibility criteria included advanced breast cancer and no taxane pretreatment. Paclitaxel was administered weekly at the dose of 90 mg/m2 (60 mg/m2 in patients at high risk of toxicity) by 1-hr i.v. infusion. Fifty-eight patients entered the trial. Median age was 54 years (range, 38-72). Performance status was good (median 1; range, 0-2). Fifty-two patients were pretreated with anthracyclines. RESULTS: A total of 1,004 weekly paclitaxel infusions were administered (median, 19 per patient; range, 4-43). The median delivered dose intensity was 67.4 mg/m2/week (range, 43-86). Twenty-eight of the 58 assessable patients obtained an objective response (48%), 15 had stable disease (26%) and 15 progressed (26%). The overall response rate was 48% (95% confidence interval, 35-61%) with 5 complete responses (8%). In anthracycline-pretreated patients, 23/52 (44%) responses were observed. Median duration of response was 5 months (range, 3-27). Toxicity was acceptable apart from a case of pulmonary embolism in a 70-year-old patient, 1 case of congestive heart failure in an anthracycline-pretreated patient aged 64, and 9 cases of G3 neutropenia. Peripheral neuropathy was observed in 38 patients (64%), usually of a mild grade; alopecia in 45 patients (78%) and onychopathy in 16 (28%), usually of a mild grade apart from 2 cases requiring treatment interruption. Tachycardia and atrial fibrillation occurred in a 55-year-old woman. CONCLUSIONS: Our data seem to confirm the activity and safety of this approach even in a heavily pretreated population of patients. Its combination with other active drugs needs to be further investigated in clinical trials.
Authors: Maryam B Lustberg; Shubham Pant; Amy S Ruppert; Tong Shen; Yong Wei; Ling Chen; Lisa Brenner; Donna Shiels; Rhonda R Jensen; Michael Berger; Ewa Mrozek; Bhuvaneswari Ramaswamy; Michael Grever; Jessie L Au; M Guillaume Wientjes; Charles L Shapiro Journal: Cancer Chemother Pharmacol Date: 2012-05-22 Impact factor: 3.333
Authors: Ana M Gonzalez-Angulo; Ian Krop; Argun Akcakanat; Huiqin Chen; Shuying Liu; Yisheng Li; Kirk S Culotta; Emily Tarco; Sarina Piha-Paul; Stacy Moulder-Thompson; Vivianne Velez-Bravo; Aysegul A Sahin; Laurence A Doyle; Kim-Anh Do; Eric P Winer; Gordon B Mills; Razelle Kurzrock; Funda Meric-Bernstam Journal: J Natl Cancer Inst Date: 2015-02-16 Impact factor: 13.506
Authors: Jeffrey A Jones; Elenir B C Avritscher; Catherine D Cooksley; Marisol Michelet; B Nebiyou Bekele; Linda S Elting Journal: Support Care Cancer Date: 2006-04-07 Impact factor: 3.603
Authors: Stacy L Moulder; Frankie A Holmes; Anthony W Tolcher; Peter Thall; Kristine Broglio; Vicente Valero; Aman U Buzdar; Susan G Arbuck; Andrew Seidman; Gabriel N Hortobagyi Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: H H Helgason; C M F Kruijtzer; A D R Huitema; S G Marcus; W W ten Bokkel Huinink; M E Schot; J H Schornagel; J H Beijnen; J H M Schellens Journal: Br J Cancer Date: 2006-09-12 Impact factor: 7.640
Authors: Mario E Lacouture; Hedy Dion; Shobha Ravipaty; Joaquin J Jimenez; Khampaseuth Thapa; Eric M Grund; Ely Benaim; Nikunj Tanna; Shen Luan; Nathaniel DiTommaso; Niven R Narain; Rangaprasad Sarangarajan; Elder Granger; Brian Berman; Shari B Goldfarb Journal: Breast Cancer Res Treat Date: 2020-11-18 Impact factor: 4.872